# Cancer Genome Dynamics (CGD) Research Program

> **NIH NIH P30** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $32,775

## Abstract

Project Summary/ Abstract:
The major focus of epigenetic mechanistic studies to date has centered on the interplay between histone or
DNA modifying proteins and transcription factors. These studies have yielded many fundamental insights
into cancer biology and novel therapeutic targets, yet recent advances suggest that an additional critical
level of control of the epigenome is conferred through the three dimensional (3D) structure of chromosomes.
The Cancer Genome Dynamics Program (CGD) is a new scientific program, composed of 46 basic and
clinical investigators from 13 departments at NYU School of Medicine and other NYU colleges. The goal of
CGD is to investigate the connections between transcription, DNA sequence, chromatin status and 3D
chromosome architecture to gain insight into how alterations at any level can initiate and/or promote tumor
formation and progression. Led by Jane Skok, PhD and William Carroll MD, the program investigates the
complex relationship between the linear and 3D genetic and epigenetic landscape of human tumors. Our
crucial and overarching objective is to translate these discoveries into novel cancer prevention and
treatment strategies. CGD research is organized into three complementary thematic aims: Aim 1: To
determine fundamental mechanisms of genetic and epigenetic regulation and their dysregulation in cancer;
Aim 2: To elucidate the role of DNA damage and repair in tumorigenesis and cancer progression; Aim 3: To
discover the changes in chromosome architecture that activate oncogenic transcriptional programs. Since
the last CCSG renewal in 2012, members have contributed 702 total publications, with 9.4% intra-
programmatic (10% since program inception in 2016), 31% inter-programmatic and 30% inter-institutional
(with NCI-CCs) publications. We have $11.4M ($3.5M NCI) in peer-reviewed funding ($14.3M total
funding). CGD is a disease-oriented thematic program with direct translational and clinical impact. During
the current funding period, CGD researchers have made new discoveries directly relevant to multiple types
of cancer, including hematological malignancies (acute myeloid leukemia, acute lymphoblastic leukemia and
multiple myeloma), breast cancer, prostate cancer, brain tumors and gynecological malignancies. Several of
these discoveries have been, or are being, translated by clinician members of CGD into clinical trials at
PCC. CGD researchers also address specific cancer burdens within our catchment area, including work on
a non-coding RNA classifier in triple negative breast cancer and a protein classifier that can distinguish
prostate cancer in African American males. Our work on DNA repair and mutagenesis is highly relevant to
unusual carcinogens in the New York City environment. CGD has pioneered and introduced new technical,
as well as bioinformatic, approaches that benefit all PCC members, and established the clinical sequencing
platform at PCC that performs over 1,000 NGS tests/year.

## Key facts

- **NIH application ID:** 10124322
- **Project number:** 5P30CA016087-40
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Jane Amanda Skok
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $32,775
- **Award type:** 5
- **Project period:** 1997-12-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10124322

## Citation

> US National Institutes of Health, RePORTER application 10124322, Cancer Genome Dynamics (CGD) Research Program (5P30CA016087-40). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10124322. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*